<DOC>
	<DOCNO>NCT00418054</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy nitazoxanide-peginterferon alfa-2b combination therapy compare peginterferon monotherapy patient treatment naive pre-treated 24 week nitazoxanide monotherapy treatment chronic hepatitis C .</brief_summary>
	<brief_title>Study Nitazoxanide Combined With Peginterferon Compared Peginterferon Monotherapy Treatment Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Age â‰¥18 year . Chronic hepatitis C infection ( least 6 month ) evidence positive enzyme immunoassay antiHCVantibodies positive quantitative RTPCR amplification HCV RNA . Chronic inflammation liver biopsy compatible diagnosis chronic viral hepatitis . HCV genotype 4 . Patients previously receive peginterferon . Patients unable take oral medication . Use ribavirin within 30 day prior enrollment . Females either pregnant , breastfeed use birth control sexually active . Any investigational drug therapy within 30 day prior enrollment Romark study number RM013027 . Patients cause liver disease . Transplant recipient receive immune suppression therapy . Patient coinfected human immunodeficiency virus , hepatitis A virus , hepatitis B virus , hepatitis D virus base enzyme immunoassay . Patients decompensated cirrhosis , thrombocytopenia ( platelet count &lt; 80,000 ) , neutropenia , history variceal bleeding , ascites , hepatic encephalopathy CTP score &gt; 6 . Patients history alcoholism ( unless abstinent 2 year ) alcohol consumption &gt; 20 gram per day . Patients clinically unstable . Patients concomitant condition , opinion investigator would preclude evaluation response make unlikely contemplated course therapy followup could complete . History hypersensitivity intolerance excipients comprise nitazoxanide tablet peginterferon alfa2b solution injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>